[HTML][HTML] FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer
…, M Hebbar, M Ben Abdelghani… - … England Journal of …, 2018 - Mass Medical Soc
Background Among patients with metastatic pancreatic cancer, combination chemotherapy
with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) leads to longer overall …
with fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) leads to longer overall …
[HTML][HTML] Tumour biology of colorectal liver metastasis is a more important factor in survival than surgical margin clearance in the era of modern chemotherapy …
…, M Elamrani, G Huet, A Duhamel, M Hebbar… - Hpb, 2015 - Elsevier
Background The aim of the authors was to reassess the impact of a positive surgical margin
(R1) after a liver resection for colorectal liver metastases (CLMs) on survival in the era of …
(R1) after a liver resection for colorectal liver metastases (CLMs) on survival in the era of …
Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated macrophage-like cells
…, E Gamelin, H Gascan, M Hebbar… - Blood, The Journal …, 2007 - ashpublications.org
… cells by enabling monocytes to consume monocyte–colony-stimulating factor (M-CSF).
Depletion of LIF, IL-6, and M-CSF in ovarian cancer ascites suppressed TAM-like cell induction. …
Depletion of LIF, IL-6, and M-CSF in ovarian cancer ascites suppressed TAM-like cell induction. …
Association of myelodysplastic syndrome and relapsing polychondritis: further evidence
M Hebbar, M Brouillard, E Wattel, M Decoulx… - …, 1995 - pubmed.ncbi.nlm.nih.gov
We report five patients with both a myelodysplastic syndrome (MDS) and relapsing polychondritis
(RP), that represented 0.6% of all MDS and 28% of all RP diagnosed over a period of …
(RP), that represented 0.6% of all MDS and 28% of all RP diagnosed over a period of …
Five-year outcomes of FOLFIRINOX vs gemcitabine as adjuvant therapy for pancreatic cancer: a randomized clinical trial
…, M Guillet, J Forestier, E Terrebonne, M Hebbar… - JAMA …, 2022 - jamanetwork.com
Importance Early results at 3 years from the PRODIGE 24/Canadian Cancer Trials Group
PA6 randomized clinical trial showed survival benefits with adjuvant treatment with modified …
PA6 randomized clinical trial showed survival benefits with adjuvant treatment with modified …
[HTML][HTML] Recent advances in epilepsy genomics and genetic testing
M Hebbar, HC Mefford - F1000Research, 2020 - ncbi.nlm.nih.gov
Developmental and epileptic encephalopathies (DEEs) are a group of severe, early onset
epilepsies characterized by refractory seizures, developmental delay or regression associated …
epilepsies characterized by refractory seizures, developmental delay or regression associated …
Interferon‐γ reverses the immunosuppressive and protumoral properties and prevents the generation of human tumor‐associated macrophages
…, S Ponsoda, Y Delneste, M Hebbar… - … journal of cancer, 2009 - Wiley Online Library
… , such as breast, prostate, cervical and ovarian cancers, the density of TAM is correlated
with poor prognosis.5, 6 TAM derive from circulating monocytes recruited locally by CCL2, M-…
with poor prognosis.5, 6 TAM derive from circulating monocytes recruited locally by CCL2, M-…
Colon cancer cells escape 5FU chemotherapy-induced cell death by entering stemness and quiescence associated with the c-Yes/YAP axis
…, P Dumont, S Truant, FR Pruvot, M Hebbar… - Clinical cancer …, 2014 - AACR
Purpose: Metastasis and drug resistance are the major limitations in the survival and management
of patients with cancer. This study aimed to identify the mechanisms underlying HT29 …
of patients with cancer. This study aimed to identify the mechanisms underlying HT29 …
Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind …
…, C Barone, LE Fein, AG Villanueva, M Hebbar… - The Lancet …, 2019 - thelancet.com
… receive cisplatin (80 mg/m 2 , on the first day) plus capecitabine (1000 mg/m 2 , twice daily for
14 … 5-Fluorouracil (800 mg/m 2 intravenous infusion on days 1–5) was permitted in patients …
14 … 5-Fluorouracil (800 mg/m 2 intravenous infusion on days 1–5) was permitted in patients …
Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on …
P Morel, M Hebbar, JL Lai, A Duhamel, C Preudhomme… - Leukemia, 1993 - europepmc.org
Although the prognostic value of cytogenetic analysis has previously been demonstrated in
myelodysplastic syndromes (MDS), karyotype had not been included in previously published …
myelodysplastic syndromes (MDS), karyotype had not been included in previously published …